Ovarian cancer immunotherapy: opportunities, progresses and challenges

被引:0
|
作者
Bei Liu
John Nash
Carolyn Runowicz
Helen Swede
Richard Stevens
Zihai Li
机构
[1] University of Connecticut School of Medicine,Department of Immunology
[2] University of Connecticut School of Medicine,Neag Comprehensive Cancer Center
[3] University of Connecticut School of Medicine,Department of Community Medicine & Health Care
来源
Journal of Hematology & Oncology | / 3卷
关键词
Ovarian Cancer; Treg Cell; Epithelial Ovarian Cancer; Dendritic Cell Vaccine; Tumor Cell Vaccine;
D O I
暂无
中图分类号
学科分类号
摘要
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
引用
收藏
相关论文
共 50 条
  • [41] Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer
    Le Saux, Olivia
    Ray-Coquard, Isabelle
    Labidi-Galy, S. Intidhar
    SEMINARS IN CANCER BIOLOGY, 2021, 77 : 127 - 143
  • [42] Screening for ovarian cancer: imaging challenges and opportunities for improvement
    Mathieu, K. B.
    Bedi, D. G.
    Thrower, S. L.
    Qayyum, A.
    Bast, R. C., Jr.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2018, 51 (03) : 293 - 303
  • [43] Drug Development and Registration: Challenges and Opportunities in Ovarian Cancer
    Ivy, S. Percy
    Kohn, Elise C.
    CANCER, 2017, 123 (14) : 2597 - 2599
  • [44] Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes
    Jennifer Anne Doherty
    Lauren Cole Peres
    Chen Wang
    Gregory P. Way
    Casey S. Greene
    Joellen M. Schildkraut
    Current Epidemiology Reports, 2017, 4 (3) : 211 - 220
  • [45] Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy
    Sachamitrt, Patty
    Hackett, Simon
    Fairchild, Paul Jonathan
    FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [46] Natural killer cell memory: challenges and opportunities for cancer immunotherapy
    Qu, Yuhua
    Zeng, Anhui
    Cheng, Yulu
    Li, Shengchun
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [47] Opportunities and challenges for targeting HPK1 in cancer immunotherapy
    Xu, Jiamei
    Li, Yingzhou
    Chen, Xinyi
    Yang, Junyi
    Xia, Heye
    Huang, Wenhai
    Zeng, Shenxin
    BIOORGANIC CHEMISTRY, 2024, 153
  • [48] Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
    John D. Martin
    Horacio Cabral
    Triantafyllos Stylianopoulos
    Rakesh K. Jain
    Nature Reviews Clinical Oncology, 2020, 17 : 251 - 266
  • [49] A Snapshot of Photoresponsive Liposomes in Cancer Chemotherapy and Immunotherapy: Opportunities and Challenges
    Youness, Rana A.
    Mohamed, Adham H.
    Efthimiadou, Eleni K.
    Mekky, Radwa Y.
    Braoudaki, Maria
    Fahmy, Sherif Ashraf
    ACS OMEGA, 2023, 8 (47): : 44424 - 44436
  • [50] Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
    Martin, John D.
    Cabral, Horacio
    Stylianopoulos, Triantafyllos
    Jain, Rakesh K.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (04) : 251 - 266